Showing results (1-10 of 10) with videos related to
Sort By:
Pageof 1
Arthritis Research & Therapy|October 28, 2011
MTRX1011A, a humanized anti-CD4 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled study incorporating pharmacodynamic biomarker assessmentsHeleen Scheerens, Zheng Su, Bryan Irving, et al.Nature Immunology|November 18, 2008
The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cellsXin Yu, Kristin Harden, Lino C Gonzalez, et al.Cancer Cell|December 4, 2014
The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector functionRobert J Johnston, Laetitia Comps-Agrar, Jason Hackney, et al.Cancer Cell|June 10, 2014
B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomasNesrine I Affara, Brian Ruffell, Terry R Medler, et al.Nature Communications|February 22, 2017
Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in miceJanet Lau, Jeanne Cheung, Armando Navarro, et al.Cancer Discovery|December 31, 2015
Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas CancerAndrew J Gunderson, Megan M Kaneda, Takahiro Tsujikawa, et al.Cancer Research|September 16, 2022
A Probody T Cell-Engaging Bispecific Antibody Targeting EGFR and CD3 Inhibits Colon Cancer Growth with Limited ToxicityLeila M Boustany, Sherry L LaPorte, Laurie Wong, et al.Cancer Research|September 18, 2014
Antitumor efficacy of a bispecific antibody that targets HER2 and activates T cellsTeemu T Junttila, Ji Li, Jennifer Johnston, et al.Proceedings of the National Academy of Sciences of the United States of America|June 26, 2021
Antitumor efficacy and reduced toxicity using an anti-CD137 Probody therapeuticIñaki Etxeberria, Elixabet Bolaños, Alvaro Teijeira, et al.Cancer Immunology Research|October 12, 2021
Conditional PD-1/PD-L1 Probody Therapeutics Induce Comparable Antitumor Immunity but Reduced Systemic Toxicity Compared with Traditional Anti-PD-1/PD-L1 AgentsHikmat H Assi, Chihunt Wong, Kimberly A Tipton, et al.Pageof 1